Table I.

Frequency (%) of baseline demographic and clinical characteristics for the overall study population and by discharge status for Induction II.

	Overall population (N = 153)	Induction II (n = 145)
		Early discharge (n = 15)	Non-early discharge (n = 130)	p-value*
Patient sex
Female	84 (54.9)	10 (66.7)	70 (53.8)	0.34
Male	69 (45.1)	5 (33.3)	60 (46.2)
Patient age
< 1 year	19 (12.4)	0 (0)	16 (12.3)	0.26
1–< 5 years	39 (25.5)	3 (20.0)	34 (26.2)
5–< 10 years	28 (18.3)	6 (40.0)	22 (16.9)
10–515 years	45 (29.4)	4 (26.7)	39 (30.0)
15 + years	22 (14.4)	2 (13.3)	19 (14.6)
Patient race
White	108 (70.6)	12 (80.0)	90 (69.2)	0.20
Black	28 (18.3)	1 (6.7)	26 (20.0)
Other	7 (4.6)	2 (13.3)	5 (3.8)
Unknown	10 (6.5)	0 (0)	9 (6.9)
Patient ethnicity
Hispanic or Latino	27 (17.6)	1 (6.7)	26 (20.0)	0.28
Not Hispanic or Latino	121 (79.1)	13 (86.7)	100 (76.9)
Unknown	5 (3.3)	1 (6.7)	4 (3.1)
Insurance status
Private or self-pay	81 (52.9)	6 (40.0)	68 (52.3)	0.64
Medicaid or Medicare	40 (26.1)	6 (40.0)	34 (26.2)
Other	3 (2.0)	0 (0)	3 (2.3)
Unknown	29 (19.0)	3 (20.0)	25 (19.2)
Risk class
High	19 (12.4)	1 (6.7)	15 (11.5)	0.67
Intermediate	106 (69.3)	10 (66.7)	93 (71.5)
Low	28 (18.3)	4 (26.7)	22 (16.9)
Treatment regimen
Standard	76 (49.7)	8 (53.3)	64 (49.2)	0.76
Standard + Gemtuzumab	77 (50.3)	7 (46.7)	66 (50.8)

Data are presented for Induction II. There were no differences in results for Intensification I–III. See Supplemental Table II for these results.

N, number of early discharge eligible patients; n, number of patients within each exposure group, early discharge or non-early discharge; Early discharge, discharge within 4 days after the last chemotherapy administration within the course.

^*p-values from Chi-square or exact test comparing the distribution of covariates among the early discharge group vs non-early discharge group.